Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on June 3, 2025
Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
GlobeNewswire
·
June 3, 2025
BRISBANE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today …
Priothera Strengthens Board with Appointment of Industry Veteran, Dr. Hans Menssen
GlobeNewswire
·
June 3, 2025
Highly experienced clinical development executive joins Priothera Board as mocravimod progresses through global Phase 3 trial as adjunctive and maintenance treatment in AML patients undergoing allo-HCT Saint-Louis, France and Dublin, Ireland – 3rd June …
Oculis to Participate in Upcoming June Investor Conferences
GlobeNewswire
·
June 3, 2025
ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs …
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
GlobeNewswire
·
June 3, 2025
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; Olmsted syndrome, severe keratoderma …
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
GlobeNewswire
·
June 3, 2025
Lehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced that two of its lead …
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
June 3, 2025
June 3, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
GlobeNewswire
·
June 3, 2025
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseases Under regulatory review in the US, the EU, and China in immune thrombocytopenia Paris, June 3, 2025. The US …
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose
GlobeNewswire
·
June 3, 2025
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose Quatrième désignation de médicament orphelin pour le rilzabrutinib dans les maladies rares En cours d’examen réglementaire aux États-Unis, …
Addex Convenes Annual General Meeting 2025
GlobeNewswire
·
June 3, 2025
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that …
Extendicare Acquires Nine Long-Term Care Homes from Revera
GlobeNewswire
·
June 3, 2025
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare”) (TSX: EXE.TO) announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc. and certain of its affiliates to acquire …